Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab
.
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-05-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241527463706624 |
|---|---|
| author | A. Pawsey P. Mahalingam N. Senthivel A. Ramessur E. Turnbull S. Usman R. Browne A. Patel A. Stewart L. Tookman N. Counsell R. Miller S. Nicum G. Eminowicz |
| author_facet | A. Pawsey P. Mahalingam N. Senthivel A. Ramessur E. Turnbull S. Usman R. Browne A. Patel A. Stewart L. Tookman N. Counsell R. Miller S. Nicum G. Eminowicz |
| author_sort | A. Pawsey |
| collection | DOAJ |
| description | . |
| format | Article |
| id | doaj-art-6e274a68294e4750bb7e0ba4cbc3ebbe |
| institution | Kabale University |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2025-05-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-6e274a68294e4750bb7e0ba4cbc3ebbe2025-08-20T04:00:08ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272025-05-0121112313110.17650/1994-4098-2025-21-1-123-131901Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumabA. Pawsey0P. Mahalingam1N. Senthivel2A. Ramessur3E. Turnbull4S. Usman5R. Browne6A. Patel7A. Stewart8L. Tookman9N. Counsell10R. Miller11S. Nicum12G. Eminowicz13University College London Hospitals NHS Foundation TrustImperial College Healthcare NHS TrustRoyal Surrey County Hospital NHS Foundation Trust, St. Luke’s Cancer CentreGuy’s and St. Thomas’ Hospitals NHS TrustRoyal Cornwall Hospitals NHS TrustColchester Hospital University NHS Foundation TrustUniversity College London Hospitals NHS Foundation TrustUniversity College London Hospitals NHS Foundation TrustRoyal Surrey County Hospital NHS Foundation TrustImperial College Healthcare NHS Trust LondonUniversity College London, Cancer Trials Centre LondonUniversity College London Hospitals NHS Foundation TrustUniversity College London Hospitals NHS Foundation TrustUniversity College London Hospitals NHS Foundation Trust.https://ojrs.abvpress.ru/ojrs/article/view/1354рак эндометрияленватинибпембролизумабпереносимостьтоксичность |
| spellingShingle | A. Pawsey P. Mahalingam N. Senthivel A. Ramessur E. Turnbull S. Usman R. Browne A. Patel A. Stewart L. Tookman N. Counsell R. Miller S. Nicum G. Eminowicz Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab Опухоли женской репродуктивной системы рак эндометрия ленватиниб пембролизумаб переносимость токсичность |
| title | Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab |
| title_full | Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab |
| title_fullStr | Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab |
| title_full_unstemmed | Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab |
| title_short | Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab |
| title_sort | real world outcomes in patients with recurrent advanced or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab |
| topic | рак эндометрия ленватиниб пембролизумаб переносимость токсичность |
| url | https://ojrs.abvpress.ru/ojrs/article/view/1354 |
| work_keys_str_mv | AT apawsey realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT pmahalingam realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT nsenthivel realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT aramessur realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT eturnbull realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT susman realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT rbrowne realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT apatel realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT astewart realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT ltookman realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT ncounsell realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT rmiller realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT snicum realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab AT geminowicz realworldoutcomesinpatientswithrecurrentadvancedormetastaticendometrialcancertreatedwithlenvatinibpluspembrolizumab |